# Fasting Study of Zonisamide Capsules 100 mg and Zonegran® Capsules 100 mg

> **NCT00650052** · PHASE1 · COMPLETED · sponsor: **Mylan Pharmaceuticals Inc** · enrollment: 107 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Zonisamide Capsules 100 mg
- **DRUG:** Zonegran® Capsules 100 mg

## Key facts

- **NCT ID:** NCT00650052
- **Lead sponsor:** Mylan Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2003-12
- **Final completion:** 2003-12
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2024-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00650052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00650052, "Fasting Study of Zonisamide Capsules 100 mg and Zonegran® Capsules 100 mg". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00650052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*